Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis

Patricia Nicolas, Marta F Maia, Quique Bassat, Kevin C Kobylinski, Wuelton Monteiro, N Regina Rabinovich, Clara Menéndez, Azucena Bardají, Carlos Chaccour, Patricia Nicolas, Marta F Maia, Quique Bassat, Kevin C Kobylinski, Wuelton Monteiro, N Regina Rabinovich, Clara Menéndez, Azucena Bardají, Carlos Chaccour

Abstract

Background: About 3·7 billion doses of ivermectin have been distributed in mass drug administration (MDA) campaigns globally over the past 30 years. At 10-100 times higher than current human doses, ivermectin is a known teratogen in mammals. During these campaigns with recommended doses, pregnant women might be inadvertently exposed. We therefore aimed to evaluate the existing evidence for serious and non-serious adverse events after ivermectin exposure in pregnant women.

Methods: For this systematic review and meta-analysis, we searched relevant databases and trial registry platforms on July 15, 2018, for randomised controlled trials (RCTs) and observational studies that reported adverse events in pregnant women. We did not use language or date restrictions. Outcomes of interest were spontaneous abortions, stillbirths, congenital anomalies, and neonatal death (serious adverse events), as well as maternal morbidity, preterm births, and low birthweight (adverse events). The risk of bias was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias Tool for RCTs. We did the meta-analysis of observational studies and RCTs separately. The quality of evidence was assessed using the GRADE approach. The study protocol is registered with PROSPERO, protocol CRD42016046914.

Findings: We identified 147 records, of which only five observational studies and one RCT were included for quantitative analysis; these studies were published between 1990 and 2008, and were done in six African countries. 893 women with 899 pregancy outcomes were included, of whom 496 pregnant women (500 pregnancy outcomes) received ivermectin inadvertently during MDA campaigns in the observational studies and 397 pregnant women (399 pregnancy outcomes) purposely received ivermectin as part of the open-label RCT. No study reported neonatal deaths, maternal morbidity, preterm births, or low birthweight. It is unclear whether exposure to ivermectin during pregnancy increases the risk of spontaneous abortions and stillbirths (odds ratio [OR] 1·15 [95% CI 0·75-1·78] with very low certainty of evidence for the four observational studies and 0·62 [0·18-2·14] with very low certainty of evidence for the RCT) or congenital anomalies (OR 1·69 [95% CI 0·83-3·41] with very low certainty of evidence for the five observational studies and 1·10 [0·07-17·65] with very low certainty of evidence for the RCT).

Interpretation: There is insufficient evidence to conclude on the safety profile of ivermectin during pregnancy. Treatment campaigns should focus additional efforts on preventing inadvertent treatment of pregnant women.

Funding: Unitaid.

Conflict of interest statement

Declaration of interests

We declare no competing interests.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1. Flowchart showing the study selection…
Figure 1. Flowchart showing the study selection process for the qualitative and quantitative synthesis
Figure 2
Figure 2
Forest plot for risk of spontaneous abortions and stillbirths after exposure to ivermectin during pregnancy compared with no exposure Evidence is from observational studies. NA=not applicable.
Figure 3. Forest plot for risk of…
Figure 3. Forest plot for risk of congenital anomalies after exposure to ivermectin during pregnancy compared with no exposure
Evidence is from observational studies.

References

    1. Merck. Stromectrol (ivermectin) 2009. [accessed Nov 4, 2019]. .
    1. Ministry of Social Affairs of Health and Women’s Rights. Stromectol 3 mg, tablet—summary of product characteristics. [accessed Nov 4, 2019; in French]. .
    1. Merck. Product information Stromectol tablets (ivermectin 3 mg) 2014. [accessed Feb 15, 2018]. .
    1. Frost L, Fujisaki T. In: Public-private partnerships for public health. Reich MR, editor. Harvard Center for Population and Development Studies; Cambridge: 2002. A partnership for ivermectin: social worlds and boundary objects; pp. 87–114.
    1. Mectizan Donation Program. annual highlights: the accomplishments of the Mectizan donation program in its 30th year. 2017. [accessed Oct 16, 2018]. .
    1. Romani L, Whitfeld MJ, Koroivueta J, et al. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med. 2015;373:2305–13.
    1. Thomsen EK, Sanuku N, Baea M, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis. 2016;62:334–41.
    1. Chaccour CJ, Kobylinski KC, Bassat Q, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12:153.
    1. Brucker MC, King TL. The 2015 US Food and Drug Administration pregnancy and lactation labeling rule. J Midwifery Womens Health. 2017;62:308–16.
    1. US FDA. Center for drug evaluation and research: approval package for Mectizan. [accessed Nov 4, 2019]. .
    1. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol. 1998;12:457–63.
    1. Brown KR. Changes in the use profile of Mectizan: 1987-1997. Ann Trop Med Parasitol. 1998;92(suppl 1):61–64.
    1. Pacque M, Munoz B, Poetschke G, Foose J, Greene BM, Taylor HR. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet. 1990;336:1486–89.
    1. Chippaux JP, Gardon-Wendel N, Ernould JC, Gardon J. Comparison between various methods of pregnancy screening during a large-scale ivermectin treatment in Cameroon. Bull Soc Pathol Exot. 1995;88:129–33.
    1. Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2003;2(suppl 1):8.
    1. Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol. 2005;289:R963–69.
    1. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006;27:602–09.
    1. Novotna M, Libra A, Kopecky M, et al. P-glycoprotein expression and distribution in the rat placenta during pregnancy. Reprod Toxicol. 2004;18:785–92.
    1. Virgintino D, Errede M, Robertson D, et al. Immunolocalization of tight junction proteins in the adult and developing human brain. Histochem Cell Biol. 2004;122:51–59.
    1. Schumacher U, Mollgard K. The multidrug-resistance P-glycoprotein (Pgp, MDR1) is an early marker of blood-brain barrier development in the microvessels of the developing human brain. Histochem Cell Biol. 1997;108:179–82.
    1. Lam J, Baello S, Iqbal M, et al. The ontogeny of P-glycoprotein in the developing human blood-brain barrier: implication for opioid toxicity in neonates. Pediatr Res. 2015;78:417–21.
    1. Tsai CE, Daood MJ, Lane RH, Hansen TW, Gruetzmacher EM, Watchko JF. P-glycoprotein expression in mouse brain increases with maturation. Biol Neonate. 2002;81:58–64.
    1. Ek CJ, Wong A, Liddelow SA, Johansson PA, Dziegielewska KM, Saunders NR. Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicol Lett. 2010;197:51–59.
    1. GSK. Albenza (albendazole) prescribing information. [accessed June 15, 2019]. .
    1. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011
    1. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
    1. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.
    1. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–06.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
    1. Burnham GM. Adverse reactions to ivermectin treatment for onchocerciasis. Results of a placebo-controlled, double-blind trial in Malawi. Trans R Soc Trop Med Hyg. 1993;87:313–17.
    1. Yumkella F. Women, onchocerciasis and ivermectin in Sierra Leone. [accessed Oct 16, 2018];1996 .
    1. Chippaux J, Gardon-Wendel N, Gardon J, Ernould J. Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy. Trans R Soc Trop Med Hyg. 1993;87:318.
    1. Doumbo O, Soula G, Kodio B, Perrenoud M. Ivermectin and pregnancy in mass treatment in Mali. Bull Soc Pathol Exot. 1992;85:247–51.
    1. Gyapong J, Chinbuah M, Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health. 2003;8:1093–101.
    1. Makene C, Malecela M, Kabali C, Charles E, Swai E, Lekashingo L. Inadvertent treatment of pregnant women in the Tanzanian mass drug administration program for the elimination of lymphatic filariasis; 52nd Annual Meeting and Centennial Celebration—; Philadelphia, USA. 2003.
    1. Ndyomugyenyi R, Kabatereine N, Olsen A, Magnussen P. Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi district, western Uganda. Am J Trop Med. 2008;79:856–63.
    1. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol. 2010;686:349–64.
    1. Blencowe H, Cousens S, Jassir FB, et al. National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. Lancet Glob Health. 2016;4:e98–108.
    1. Turner HC, Walker M, Churcher TS, Basanez MG. Modelling the impact of ivermectin on river blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections. Parasit Vectors. 2014;7:241.
    1. Chaccour C, Rabinovich NR. Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway. Malar J. 2017;16:166.
    1. Chaccour C, Rabinovich NR. Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways. Malar J. 2017;16:162.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir